Business Context and Reporting Period
Enovix Corporation filed a Form 8-K dated November 10, 2022, reporting the appointment of Ajay Marathe as Chief Operating Officer. His employment commenced November 14, 2022. The filing was signed on November 14, 2022.
Financial and Operating Metrics
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics.
Material Changes Versus the Prior Comparable Period
- Ajay Marathe was appointed Chief Operating Officer, succeeding no specifically identified predecessor in the filing.
- Mr. Marathe brings prior operations leadership experience at Western Digital Technologies, Lumileds, Solaria, and Advanced Micro Devices.
Compensation, Outlook, and Risks
- Annual base salary: $450,000.
- Target annual discretionary cash bonus: 80% of base salary, subject to performance goals, the Annual Incentive Plan, and Board approval.
- Equity award: restricted stock units covering 833,000 shares under the 2021 Equity Incentive Plan. One-fifth vests after 12 months, with the remainder vesting monthly over four years, subject to continued service.
- Upon specified qualifying terminations, subject to applicable conditions and a release of claims, benefits may include nine months of base salary, up to nine months of health-care coverage, a prorated target bonus, and acceleration of equity vesting corresponding to 18 additional months of service.
- For qualifying terminations occurring within the specified period surrounding a change of control, the executive may receive the foregoing severance benefits plus acceleration of 75% of then-unvested equity after other applicable acceleration.
- The employment offer letter will be filed as an exhibit to the Company’s Form 10-K for the period ending January 1, 2023.
Key Facts to Verify
- Verify the final terms of the offer letter when filed with the Form 10-K.
- Assess the potential dilution from the 833,000-share RSU award and any subsequent equity awards.
- Review the effect of the new COO’s appointment on manufacturing execution, capacity expansion, and commercialization plans.
- Evaluate the potential cost of severance, health-care continuation, bonus payments, and accelerated vesting under applicable termination or change-of-control scenarios.